

CAP TODAY

WHERE THE WORLD OF THE CLINICAL LABORATORY COMES TOGETHER

Publisher's Picks eBlast Banners

CAP TODAY Publisher Bob McGonnagle: A Trusted Voice in Laboratory Medicine

For nearly four decades, Bob McGonnagle, the esteemed publisher of CAP TODAY, has been a prominent figure in the field of medical laboratory medicine. Recognized by pathologists, lab leaders, and industry experts alike, Bob's deep industry knowledge is as distinctive as his trademark bow tie.

Bob chooses the articles to include in the blast—those that readers seek out and visit most frequently. These topics evolve with the changing priorities of the laboratory world, ensuring our content remains relevant and impactful.

This exclusive eblast reaches 140,000 subscribers, offering you a unique opportunity to promote your brand at a highly competitive rate.

► eBlast includes:

Four 300 × 250 spots available, one/advertiser

\$1,700

High-impact, low-cost option


For more information and availability contact:


West: Lori Prochaska | 402-290-7670 | lori@captoday.org

Midwest: Alex Pacheco | 402-290-8203 | alex@captoday.org


East: Lori Prochaska and Alex Pacheco | lori@captoday.org and alex@captoday.org

Sales and Support: Nicole Quackenbush | 402-960-2869 | nicole@captoday.org


Publisher's Picks



Welcome to the second of CAP TODAY's Publisher's Pick eblasts for 2025. This series highlights the most impactful articles from the second quarter of the year, handpicked by me for their relevance and importance to diagnostics and laboratory medicine. While every article we publish is carefully curated for our loyal readership, these selections stand out as exceptional. — *Bob McGonnagle*





For myeloid malignancies, how WHO-HEM5 and ICC differ

How the World Health Organization fifth edition of hematolymphoid tumors and the International Consensus Classification differ for myeloid malignancies was highlighted in cases presented in a CAP24 session last fall.

Taking on low, ultralow HER2 breast cancer

Since the hunt began to identify low levels of HER2 in metastatic breast cancers, the action has revealed itself like the plot of a Henry James novel: Nothing much happens. Also, a lot happens. And each narrative thread is conveyed in hard-to-parse language.






Tumor marker testing in body fluids calls for caution

With few FDA-cleared or -approved methods for tumor marker testing in body fluids, it is the laboratory that's responsible for the tests. "A specimen arrives at your door, and you have to figure out what, if anything, you're going to do," said Jonathan Genzen, MD, PhD.

Not to be overlooked: lab administrative skill

The transition from pathology training to practice is not just about diagnostic skill and confidence in that skill but also laboratory administrative duties



PUBLISHERS PICKS EBLAST BANNERS